Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
Erkut Hasan BorazanciNathan BaharyVincent ChungTimothy K HuyckEbenezer A KioElena Gabriela ChioreanRoland T SkeelOlatunji B AleseDana B CardinChristos FountzilasWahid T HannaAlexis D LealValerie LeeAnne M NoonanPhilip A PhilipZev A WainbergHristina PashovaGrace MannPaul E ObersteinPublished in: The oncologist (2024)
Relacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.